Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale Director sold 20,000 shares at an average $35.61 ($712,110)
  2. 4 Option exercise Director acquired 62,500 shares (option exercise)
  3. 4/A Open-market sale Director sold 20,000 shares at an average $33.83 ($676,583)
  4. 4 Returned to the company Director returned 60,000 shares (to the company)
  5. 4 Grant or award Director acquired 5,986 shares (grant or award)
  6. 4 Grant or award Director acquired 5,986 shares (grant or award)
  7. 4 Grant or award Director acquired 5,986 shares (grant or award)
  8. 4 Grant or award Director acquired 5,986 shares (grant or award)
  9. 4 Grant or award Director acquired 5,986 shares (grant or award)
  10. 4 Grant or award Director acquired 5,986 shares (grant or award)
  11. 4 Grant or award Director acquired 5,986 shares (grant or award)
  12. 4 Grant or award Director acquired 5,986 shares (grant or award)
  13. 4 Open-market sale Director sold 20,000 shares at an average $33.83 ($676,583)
  14. 5 Insider Annual Insider Trading Report
  15. 4 Open-market sale President and CEO sold 9,491 shares at $34.72 ($329,528)
  16. 4 Open-market sale CFO and Treasurer sold 2,560 shares at $34.69 ($88,806)
  17. 4 Open-market sale COO and Secretary sold 2,803 shares at $34.68 ($97,208)
  18. 4 Open-market sale Chief Medical Officer sold 2,918 shares at $34.71 ($101,284)
  19. 3/A Insider 3/A
  20. 4 Open-market sale CFO and Treasurer sold 1,296 shares at $37.09 ($48,073)

Page 9 of 22 · 436 filings